
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
The financial analyst highlights that IGC Pharma Inc.'s stock presents an attractive valuation with recent adjustments indicating substantial upside potential based on net present value (NPV) analyses. Notably, IGC-AD1 has demonstrated significant promise in preclinical studies, showing a statistically significant reduction in agitation among Alzheimer's patients compared to placebo, which may serve as a catalyst for positive market movement. The ongoing development of several investigational drug assets targeting Alzheimer's disease and related conditions further enhances the outlook for the company's future growth and profitability.
Bears say
IGC Pharma reported a net loss of $0.7 million, with earnings per share of $(0.01), which was slightly better than estimated but still indicates ongoing financial challenges. The company is projected to generate only $0.2 million in revenue, falling short of consensus estimates of $0.3 million, highlighting operational difficulties and potential market risks. Additionally, IGC Pharma faces numerous obstacles including liquidity risks, the uncertain success of its investigational drug candidates, and challenges related to regulatory approvals and commercialization, which contribute to a negative outlook on its stock performance.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares